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Protection of the ischaemic heart: investigations into the 
phenomenon of ischaemic preconditioning
A LOChNER, E MARAIS, S GENADE, B huISAMEN, EF Du TOIT, JA MOOLMAN
summary
Exposure of the heart to one or more short episodes of 
ischaemia/reperfusion protects the heart against a subse-
quent prolonged period of ischaemia, as evidenced by a 
reduction in infarct size and an improvement in functional 
recovery during reperfusion. Elucidation of the mechanism 
of this endogenous protection could lead to the development 
of pharmacological mimetics to be used in the clinical setting. 
The aim of our studies was therefore to gain more informa-
tion regarding the mechanism of ischaemic preconditioning, 
using the isolated perfused working rat heart as model.
A preconditioning protocol of 1 × 5 or 3 × 5 min of isch-
aemia, interspersed with 5 min of reperfusion was found 
to protect hearts exposed to 25 min of global ischaemia or 
35–45 min of regional ischaemia. These models were used 
throughout our studies. 
In view of the release of catecholamines by ischaemic 
tissue, our first aim was to evaluate the role of the alpha-
adrenergic receptor in ischaemic preconditioning. However, 
using a multi-cycle ischaemic preconditioning protocol, we 
could not find any evidence for alpha-1 adrenergic or PKC 
activation in the mechanism of preconditioning. Cyclic 
increases in the tissue cyclic nucleotides, cAMP and cGMP 
were found, however, to occur during a multi-cycle precon-
ditioning protocol, suggesting roles for the beta-adrenergic 
signalling pathway and nitric oxide (NO) as triggers of 
cardioprotection. This was substantiated by the findings that 
(1) administration of the beta-adrenergic agonist, isopro-
terenol, or the NO donors SNAP or SNP before sustained 
ischaemia also elicited cardioprotection similar to ischaemic 
preconditioning; (2) beta-adrenergic blockade or nitric 
oxide synthase inhibition during an ischaemic precondition-
ing protocol abolished protection. Effectors downstream of 
cAMP, such as p38MAPK and CREB, were also demonstrat-
ed to be involved in the triggering process.
Our next step was to evaluate intracellular signalling 
during sustained ischaemia and reperfusion. Our results 
showed that ischaemic preconditioned-induced cardiopro-
tection was associated with a significant reduction in tissue 
cAMP, attenuation of p38MAPK activation and increased 
tissue cGMP levels and HSP27 activation, compared to 
non-preconditioned hearts. The role of the stress kinase 
p38MAPK was further investigated by using the inhibitor 
SB203580. Our results suggested that injury by necrosis and 
apoptosis share activation of p38MAPK as a common signal 
transduction pathway and that pharmacological targeting of 
this kinase offers a tenable option to manipulate both these 
processes during ischaemia/reperfusion injury.
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Cardiovascular disease remains a leading cause of morbidity and 
mortality in the western world and according to the predictions 
of the World Health Organisation, it will be the major cause of 
death worldwide by the year 2020.1 There is therefore continued 
interest in developing new drugs and interventions that will limit 
the extent of infarction and prevent cell death.
The discovery by Murry and co-workers in 1986,2 that expo-
sure of the heart to four cycles of 5-min ischaemia, interspersed 
with 5 min of reperfusion significantly reduced infarct size, 
indicated that the heart has a significant endogenous protective 
mechanism at its disposal. This phenomenon, termed ischaemic 
preconditioning, has been recognised as the ‘strongest form of in 
vivo protection against myocardial ischaemic injury other than 
early reperfusion’.3 This, in turn, has led to an enormous effort to 
elucidate the mechanism of preconditioning, the rationale being 
that should the mechanism of protection be known, it could lead 
to the development of pharmacological mimetics to be used 
in the clinical setting. The interest that this phenomenon has 
evoked is also reflected in the large number of reviews that have 
appeared on the topic.4-6 This phenomenon was subsequently 
found to occur in all species and organs tested (for a review see 
reference 4).
In 1991, our laboratory decided to join the race for the 
discovery of the mechanism of ischaemic preconditioning. Our 
first task was to develop and characterise a model of ischae-
mic preconditioning, using the isolated, perfused, working rat 
heart as experimental model. Using functional recovery during 
reperfusion as the endpoint, we found that subjecting hearts to 
a preconditioning protocol of one episode of 5 min of global 
ischaemia, followed by 5 min of reperfusion, before a sustained 
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global ischaemic period of 25 min, caused a significant improve-
ment in post-ischaemic function and structural appearance.7 
However, controversial results obtained by workers using 
different animal species, experimental protocols, models and 
endpoints prompted us to re-evaluate the role of the model 
(retrograde vs working heart perfusion), endpoints (functional 
recovery vs infarct size) and degree of ischaemia (global vs 
regional ischaemia), respectively, in the outcome of prior 
preconditioning. The results obtained showed that while the 
working, preconditioned rat heart (1 × 5 min ischaemia) showed 
a significant improvement in post-ischaemic functional recovery, 
it was more difficult to demonstrate improved function in the 
retrogradely perfused heart. Preconditioning of working hearts 
showed a significant decline in infarct size after both 30 and 35 
min regional ischaemia, while the retrogradely perfused heart 
showed a significant decline after 35 min only. The results also 
indicated that infarct size was a more reliable endpoint than func-
tional recovery.8 In fact, most workers in the field currently use 
infarct size as the gold standard for evaluation of cardioprotec-
tion induced by prior preconditioning.
Characterisation of events during an  
ischaemic preconditioning protocol
To gain more information regarding the mechanism of precon-
ditioning, we argued that knowledge of events during an ischae-
mic preconditioning protocol is a prerequisite for identifying 
the mechanisms involved. It is now well established that three 
endogenous triggers are released during exposure of the heart 
to short episodes of ischaemia/reperfusion, namely adenosine, 
opioids and bradykinin (for a review see references 9, 10). Their 
respective roles in eliciting protection have been demonstrated 
using appropriate receptor agonists and antagonists, which were 
able to elicit or abolish cardioprotection, respectively.
The role of the release of endogenous catecholamines in 
eliciting preconditioning received surprisingly little attention. 
Ischaemia-mediated release of catecholamines and a concomi-
tant increase in tissue cAMP have been known for many years,11 
and in the initial studies on preconditioning, a role for the α1-
adrenergic receptor was proposed.12
Therefore, our first attempt to elucidate the mechanism 
of ischaemic preconditioning was aimed at establishing the 
involvement of the α1-adrenergic signalling pathway and its 
downstream substrate PKC. Using a preconditioning protocol 
of 3 × 5 min global ischaemia in the working rat heart model, 
we tested the effectiveness of preconditioning in the presence 
of the α1-adrenergic blocker, prazosin, and the selective PKC 
blockers, chelerythrine and bisindolylmaleimide, as well as the 
ability of repetitive α1-adrenergic activation using phenylephrine 
to mimic preconditioning. In this model, we could not find any 
evidence for α1-adrenergic or PKC activation in the mechanism 
of preconditioning.13 In retrospect, it is possible that the multi-
cycle preconditioning protocol (3 × 5 min) used in these experi-
ments was the reason for these negative results because it is now 
known that such a preconditioning protocol elicits a powerful 
form of protection, which is more difficult to inhibit than a single 
episode.4
The observation that the cyclic nucleotides cAMP and cGMP 
increased in a cyclic fashion at the end of each preconditioning 
episode suggested roles for the beta-adrenergic signal transduc-
tion system as well as NO14-16 as triggers in the preconditioning 
process (Fig. 1).
The contribution of β-adrenergic receptor stimulation to trig-
gering preconditioning was proven by the use of appropriate 
agonists and antagonists: administration of the β1-adrenergic 
blocker, alprenolol (7.5 × 10-5 M) during the triggering phase 
significantly attenuated (but did not abolish) cardioprotec-
tion,15 whereas pharmacological activation of the β-adrenergic 
receptor (1 × 5 min administration of 10-6–10-8 M isoproterenol) 
caused a significant improvement in functional recovery during 
reperfusion,15 as well as a reduction in infarct size17 (Figs 2, 3). 
Pharmacological preconditioning with β-adrenergic activation 
(the so-called beta-adrenergic preconditioning) has also been 
demonstrated by Nasa et al.,18 Asimakis and Conti19 and Robinet 
et al.20 
The role of the cyclic increases in cGMP in eliciting cardio-
protection was subsequently investigated, using a similar experi-
mental approach to that above.14 Tissue cyclic nucleotides were 
manipulated using NO donors [e.g. S-nitroso-N-penicillamine 
(SNAP) and sodiumnitroprusside (SNP)] and inhibitors of nitric 
oxide synthase (NOS) (e.g. L-NAME or LNA). Pharmacological 
elevation in tissue cGMP levels by SNAP or SNP before 
Fig. 1. tissue cAMP and cgMP levels during a multi-cycle 
preconditioning protocol. PC1-, PC2-, PC3-: first, second 
and third episodes of 5 min of global ischaemia. PC1+, 
PC2+, PC3+: first, second and third episodes of reper-
fusion after ischaemia.
(*p<0.05 vs control)
(# p<0.05 vs PC1-)
($ p<0.05 vs PC2-)
(& p<0.05 vs PC3-) Fig. 2. Functional performance during reperfusion after 25 min of global ischaemia. non-PC: non-preconditioned 
hearts; PC: ischaemic preconditioned (3 × 5 min); PC + 
Alp: ischaemic preconditioned (3 × 5 min) + alprenolol 
(7.5 × 10-5 M) added during the preconditioning protocol; 
iso: beta-adrenergic preconditioning with isoproterenol 
(1 × 5 min; 10-6 M).
† p < 0.001 vs Control
# p < 0.001 vs non-PC
* p < 0.01 vs PC
n > 6 hearts/group
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l/m
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sustained ischaemia improved post-ischaemic functional recov-
ery comparable to that of ischaemic preconditioning (Fig. 4), 
while administration of the NOS inhibitors before and during the 
preconditioning protocol attenuated functional recovery (Fig. 5). 
Later studies confirmed that exogenous NO was able to 
elicit preconditioning-induced protection.4 Subsequent studies 
also emphasised the significance of cGMP and activation of 
PKG in the triggering of preconditioning. In 2005, Costa et al.21 
showed that addition of exogenous PKG and cGMP to isolated 
mitochondria resulted in the opening of the mitochondrial KATP 
channels, via PKCε. This, in turn, leads to the generation of reac-
tive oxygen species (ROS), which acts as a second messenger in 
triggering cardioprotection.22,23
signalling events during triggering of  
preconditioning
Having established the involvement of the second messengers, 
cAMP and cGMP in triggering ischaemic and pharmaco-
logical preconditioning, we investigated the downstream signal-
ling events, focusing on the mitogen-activated protein kinase 
(MAPKinase) family. Each subfamily of the MAPK family, 
ERK, JNK and p38 MAPK, has been suggested to play a role 
in the cardioprotection elicited by prior preconditioning (for 
reviews see references 24, 25). In view of the many controversial 
results obtained, we decided initially to focus on the role of p38 
MAPK as a trigger by evaluating its activation pattern during a 
multi-cycle ischaemic preconditioning protocol and during β-
adrenergic preconditioning. 
The results showed that although p38 MAPK is significantly 
activated during the first and second ischaemic precondition-
ing episodes, the activation is transient and disappears after the 
third episode (Fig. 6).26 Beta-adrenergic preconditioning with 
isoproterenol also caused a significant dose-dependent activa-
tion of the kinase within three minutes. These cyclic elevations 
in p38 MAPK during an ischaemic preconditioning protocol are 
most likely due to the release of substances acting as triggers, 
for example endogenous catecholamines. The transient nature 
of p38 MAPK activation does not argue against its putative role 
as trigger of protection, since its downstream effects may persist 
long after its initial activation.26
The triggering action of p38 MAPK activation in both ischae-
mic and β-adrenergic preconditioning was further substantiated 
by the finding that β-adrenergic blockade with alprenolol during 
the preconditioning protocol inhibited p38 MAPK activation, 
and inhibition of its activation by SB 203580 in β-adrenergic 
preconditioning abolished cardioprotection. However, a number 
of observations argued against p38 MAPK activation as the 
only trigger in a multi-cycle preconditioning protocol, since 
bracketing this protocol with SB203580 did not abolish protec-
tion.26 Schneider and co-workers,27 using the p38MAPK inhibi-
tor SB202190, also failed to block preconditioning-induced 
improvement in contractile recovery and reduction in infarct size 
in an isolated rat heart model. 
However, we have subsequently shown that SB203580 abol-
ishes cardioprotection elicited by a single-episode precondition-
ing protocol, which indicates that the other triggers known to be 
involved in a multi-cycle protocol may override the triggering 
actions of p38 MAPK.28 The triggering role of p38 MAPK was 
further substantiated by using anisomycin, an activator of p38 
MAPK,28 which could also elicit cardioprotection, as evidenced 
by a reduction in infarct size.
At this stage, the sequence of events downstream of p38 
MAPK still needed further investigation. MAPKAPK-2 and 
-3 (mitogen-activated protein kinase-activated protein kinase 2 
and 3) and PRAK (p38-regulated and activated kinase), located 
downstream of p38 MAPK29,30 are known to phosphorylate the 27 
kDa small heat-shock protein (HSP27), which has been shown 
to protect against ischaemic stress.31 We therefore evaluated the 
role of HSP27 as downstream effector of p38 MAPK during an 
ischaemic or β-adrenergic preconditioning protocol.32 
Interestingly, the marked, but transient activation of p38 
MAPK during a multi-cycle ischaemic preconditioning protocol 
was associated with sustained activation of HSP27 throughout 
this procedure (Fig. 7). Similar changes in p38 MAPK and HSP27 
occurred during β-adrenergic preconditioning. Pretreatment with 
SB 203580 abolished activation of both p38 MAPK and HSP27, 
suggesting that p38 MAPK activation triggers HSP27 phospho-
rylation. Both these events appear to be important in eliciting 
cardioprotection, since inhibition with SB203580 abolished 
protection, as indicated by a reduction in functional recovery and 
an increased infarct size.32
Finally, the role of the transcription factor, cyclic AMP 
response element-binding protein (CREB), as possible down-
stream effector of p38 MAPK was evaluated during an ischae-
Fig. 3. Effect of ischaemic (iPC) and beta-adrenergic 
preconditioning (BPC) on infarct size after 35 min of 
regional ischaemia. nPC: non-preconditioned hearts. 
infarct size is expressed as a percentage of the area at 
risk.
Fig. 4. Pharmacological preconditioning with no donors. 
snAP: s-nitroso-n-penicillamine, 50 µM; snP: sodium 
nitroprusside, 100 µM; l-Arg: l-arginine (10 mM).
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mic preconditioning protocol.33 As in the case of HSP27, CREB 
was activated by exposure of the heart to 5 min of ischaemia, 
followed by reperfusion, and it remained activated throughout 
the multi-cycle ischaemic preconditioning protocol. Release of 
endogenous catecholamines activates CREB via both the α1- and 
β1-adrenergic receptors, while the adenosine A1 and A3 receptors 
are also involved, as indicated by the use of selective antagonists 
(Fig. 8). CREB activation by events downstream of receptor 
stimulation included activation of PKA, PKC, ERK, MSK-1 and 
p38 MAPK. These observations indicate that CREB may well be 
a convergence point for several signalling pathways during the 
triggering process of preconditioning33 (Fig. 9).
Interestingly, both the Ca2+-independent (iPLA2) and cytosolic 
(cPLA2) phospholipases are involved in CREB activation during 
ischaemia/reperfusion. This was demonstrated by the use of the 
inhibitors 4-bromo-enol-lactone and AACOF3, respectively.
33 
These phospholipases also play a significant role in cardiopro-
tection, since administration of these inhibitors during a single-
cycle preconditioning protocol significantly increased infarct 
size. As far as we know, this was the first demonstration of the 
involvement of these phospholipases in ischaemic precondition-
ing, and their significance in this scenario needs to be further 
investigated.
Finally, our data confirm the crucial role of p38 MAPK and 
its downstream targets, for example, HSP27 and CREB in trig-
gering the cardioprotection of both ischaemic and β-adrenergic 
Fig. 7. Phosphorylation pattern of hsP27 in cytosolic 
fraction during an ischaemic preconditioning protocol. 
PC1-, PC3-: first and third episodes of 5 min of ischaemia; 
PC1+, PC3+: first and third episodes of 5 min of reper-
fusion after ischaemia.
Fig. 5. Functional performance during reperfusion after 25 min of global ischaemia: effect of nos inhibition with l-
nAME [n(omega)-nitro-l-arginine methyl ester], (50 µM).
Fig. 6. Phosphorylation pattern of p38 MAPK during an 
ischaemic preconditioning protocol. PC1-, PC3-: first and 
third episodes of 5 min of ischaemia; PC1+, PC3+: first 
and third episodes of 5 min of reperfusion after ischae-
mia.
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preconditioning. A recent study by Nagy et al.34 indicated that 
MSK-1 is an alternative (other than MAPKAPK-2 and HSP27) 
downstream target for p38 MAPK, which then transmits the 
survival signal through activation of CREB. In view of the above, 
it is possible that gene expression was activated during a multi-
cycle preconditioning protocol. However, events downstream 
of CREB phosphorylation and their link(s) to cardioprotection 
during sustained ischaemia and particularly during reperfusion 
still remain to be established.
signalling events during sustained ischaemia 
and reperfusion
Cyclic nucleotides
After having established that the ischaemic preconditioning 
process can be triggered by, among others, β-adrenergic stimula-
tion as well as NO and a number of the downstream events in 
this process, we characterised events during sustained ischaemia 
in an attempt to gain more information regarding the effectors 
of protection.
Our initial study focused on the possibility that prior precon-
ditioning protects via energy sparing during sustained ischae-
mia. Careful monitoring of tissue high-energy phosphate and 
glycogen levels, as well as lactate accumulation suggested that 
prior preconditioning reduced energy utilisation during sustained 
ischaemia in preconditioned hearts.7 Similar energy-sparing 
effects were reported by others.35,36 Whether these changes were 
sufficient to account for the improvement in recovery or whether 
they are merely the consequence of protection elicited by precon-
ditioning, needs to be further investigated.
In view of the role of β-adrenergic stimulation as trigger, 
our next step was to evaluate this particular signalling pathway 
during sustained ischaemia. The deleterious consequences of 
activation of the β-adrenergic signal transduction pathway in 
myocardial ischaemia are widely appreciated. Indeed, our results 
showed that cAMP accumulation during sustained ischaemia 
was significantly less in preconditioned hearts,37 and associ-
ated with upregulation of cAMP- and cGMP-phosphodiesterase 
activities.16 (Fig. 10).
Reduced cAMP accumulation during sustained ischaemia was 
also observed in preconditioned rabbit hearts.38,39 The question 
was then raised whether the reduction in cAMP was the cause or 
result of preconditioning-induced protection. Our approach was 
to evaluate the characteristics of the different members of the β-
adrenergic signal transduction pathway at the onset of sustained 
ischaemia (i.e. immediately after ischaemic preconditioning). 
The Bmax of the β-receptor was found to be increased by 39% and 
its Kd decreased by 35%. Adenylyl cyclase and PKA activations 
were reduced at this stage and desensitised to further β-adrener-
gic stimulation.15 Similar reduced responsiveness to β-adrenergic 
signal transduction in preconditioned hearts was reported by 
Simonis et al.40
To assess whether a reduced tissue cAMP content per se is 
related to cardioprotection, tissue cAMP was elevated experi-
mentally by administration of forskolin (which directly activates 
adenylyl cyclase) to preconditioned hearts. Although it markedly 
increased tissue cAMP levels during sustained ischaemia, it did 
not abolish protection.37 Sandhu and co-workers38 used NKH477 
to activate adenylyl cyclase during ischaemia and likewise 
found no loss of protection in rabbit hearts. These data strongly 
suggested that the reduced cAMP levels during sustained ischae-
mia in preconditioned hearts were probably merely a reflection 
of protection, rather than a causal factor.
In contrast to cAMP, a significant increase in tissue cGMP 
during sustained ischaemia was observed in preconditioned 
hearts.14 The significance of NOS and GMP as triggers in classic 
preconditioning was discussed in the previous section. However, 
little is known about the role of cGMP during sustained ischae-
mia of the preconditioned heart. It is known to reduce intracel-
lular Ca2+ and cause vasorelaxation.41 It has also been shown 
that exogenous PKG and cGMP, when added to isolated mito-
chondria, resulted in opening of the mitochondrial KATP chan-
nels.21 Whether this contributes to protection of the heart during 
sustained ischaemia as well remains to be established.
p38MAPK
The role of p38 MAPK activation during sustained ischaemia 
and reperfusion was the next to be addressed.26,28,32 It was known 
that myocardial ischaemia/reperfusion activates p38 MAPK in 
Fig. 8. Phosphorylation of CrEB by ischaemia/reper-
fusion and forskolin (1 µM). inhibition of ischaemia/reper-
fusion-induced phosphorylation of CrEB by propranolol 
(0.1 µM), prazosin (0.3 µM), dPCPX (adenosine A1 recep-
tor blocker, 1 µM) and Mrs-1191 (adenosine A3 receptor 
blocker, 5 µM).
Fig. 9. signalling pathways involved in CrEB phosphor-
ylation by endogenous catecholamines, adenosine and 
phospholipase A2 activation.
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most species,42-44 with the exception of the rabbit heart.45,46 In our 
study, dual phosphorylation and activation of p38 MAPK were 
monitored at 5, 10, 15 and 25 min of sustained global ischaemia 
of non-preconditioned and ischaemic preconditioned hearts. 
p38MAPK was significantly less in preconditioned than in non-
preconditioned hearts during both ischaemia and reperfusion 
(Figs 11, 12).26 This pattern was also observed in β-adrenergic 
preconditioning, or hearts preconditioned with the NO donors 
SNAP and SNP.47 Conversely, inhibition of preconditioning 
during the triggering phase by β-blockade, p38 MAPK inhibi-
tion or NOS inhibition, resulted in an increase in p38 MAPK 
activation during sustained ischaemia, similar to that observed in 
non-preconditioned hearts. 
In summary, in our hands, attenuation of p38 MAPK activa-
tion during sustained ischaemia and reperfusion was associated 
with improved mechanical recovery during reperfusion and a 
reduction in infarct size.17,26 Conversely, maintained high levels of 
p38 MAPK activation during ischaemia/reperfusion were present 
in hearts that failed to recover mechanically and failed to show a 
reduction in infarct size.17
Significantly less p38 MAPK activation has also been 
reported in preconditioned rat myoblasts29 and perfused hearts,48 
as well as dog hearts in vivo.44 Inhibition of p38 MAPK during or 
immediately before sustained ischaemia, by administration of the 
inhibitors SB203580 or SB202190, is also cardioprotective.49,50 
Perhaps the most convincing evidence in this regard came 
from a study on neonatal myocytes.51 Not only did SB203580 
reduce ischaemic injury, but prior preconditioning of these cells 
prevented p38α MAPK activation during ischaemia. Moreover, 
cells expressing a dominant negative p38α, which prevented p38 
MAPK activation, were resistant to lethal ischaemia. 
Despite these convincing data, other workers published contra-
dictory findings, suggesting an association between increased 
activation of p38MAPK and cardioprotection.45,52 It would 
appear that the outcome of p38 MAPK activation in ischaemia 
is dependent on the isoform activated and it is possible that the 
p38 MAPK isoforms are differentially activated by ischaemic 
preconditioning. It has been demonstrated that transgenic mice 
over-expressing p38α-MAPKdn were significantly protected 
from myocardial ischaemia/reperfusion injury.53 Determining the 
precise role of the p38 MAPK pathway in ischaemic damage will 
ultimately rely on the development of p38 MAPK isoform-selec-
Fig. 12. p38 MAPK phosphorylation during reperfusion 
after 25 min global ischaemia: effect of prior ischaemic 
preconditioning (3 × 5 min).
Fig. 11. p38 MAPK phosphorylation during sustained 
global ischaemia: effect of prior ischaemic precondition-
ing (3 × 5 min).
Fig. 10. tissue cAMP and cgMP changes during sustained global ischaemia: effect of prior ischaemic preconditioning 
(3 × 5 min).
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tive inhibitors and new p38 MAPK-targeting agents.54
However, despite conflicting results reported regarding p38 
MAPK activation in cardioprotection, our results obtained in the 
perfused rat heart provide strong evidence of a detrimental role 
of p38 MAPK activation in the setting of ischaemia/reperfusion. 
Our subsequent studies were therefore aimed at determining how 
attenuation of p38MAPK activation confers protection against 
ischaemia/reperfusion damage.
how does attenuation of p38 MAPK activation 
protect the heart against ischaemic damage?
Ischaemic preconditioning protects the myocardium against the 
various deleterious effects of ischaemia, such as necrosis2 and 
apoptosis.55,56 It is well established that necrosis occurs during 
ischaemia as well as during early reperfusion, while apoptosis 
occurs mainly during reperfusion,57,58 the latter making an inde-
pendent contribution to reperfusion injury. It has been suggested 
that the stress kinases may activate important signal transduc-
tion pathways in apoptosis, caused by ischaemia/reperfusion.59 
For example, Ma and co-workers60 showed that activation of 
p38 MAPK during myocardial ischaemia/reperfusion caused 
apoptosis. 
Since the role of attenuation of p38 MAPK activation in 
protection against apoptosis in ischaemic preconditioning was 
not known at that stage, we investigated whether the reduction in 
apoptosis known to occur in ischaemic preconditioning was the 
result of inhibition of p38 MAPK during ischaemia/reperfusion 
and whether β-adrenergic preconditioning also protected against 
apoptosis.
We also attempted to establish whether activation of p38 
MAPK during the preconditioning protocol (trigger phase) was 
involved in the anti-apoptotic effect of both ischaemic and β-
adrenergic preconditioning.17 In this study, apoptosis was meas-
ured by caspase-3 activation and PARP cleavage. 
Our results showed that attenuation of p38 MAPK activation 
during sustained ischaemia of both ischaemic and β-adrenergic 
preconditioned hearts was associated with a reduction in apop-
tosis as well as infarct size. These results suggested that injury 
by necrosis and apoptosis share activation of p38 MAPK as a 
common signal transduction pathway and that pharmacological 
targeting of p38 MAPK offers a tenable option to manipulate 
both apoptosis and necrosis during ischaemia/reperfusion injury. 
Interestingly, in contrast to the many investigations focusing 
on the role of the kinases (p38MAPK in particular), very little 
indeed is known about the role of the phosphatases in this 
scenario.
Co-existence of attenuated p38 MAPK activation and cardio-
protection does not indicate causality and the question remains, 
as in the case of cAMP levels in ischaemia, whether attenua-
tion of this stress kinase is merely a reflection of the protected 
myocardium or whether it causes protection. In a study on the 
temporal relationship between p38 MAPK and HSP27, we 
found that attenuation of p38 MAPK during sustained ischaemia 
of ischaemic preconditioned and β-adrenergic preconditioned 
hearts was associated with phosphorylation of both cytosolic and 
myofibrillar HSP27 (Fig. 13).32 
The cardioprotective actions of the small heat-shock proteins 
are well-established.31,61,62 For example, over-expression of HSP27 
in cultured cardiac cells has a potent cardioprotective effect,62,63 
and mice over-expressing HSP 27 were protected from lethal 
ischaemia/reperfusion injury.64 HSPs may confer protection 
in several ways, for example they may act as chaperones,65 or 
stabilise the cytoskeleton66 or actin to accelerate recovery from 
stress.67,68 A recent study reported a novel role for HSP27 in 
cardioprotection: it protected cardiac troponin I and troponin T 
from ischaemia/reperfusion-induced degradation by preventing 
their proteolytic clearage via interaction with these proteins. 
Such protection resulted in restored post-ischaemic myofilament 
response to Ca2+ and improved contractile function.69 These data 
suggest that increased activation of the small heat-shock proteins 
during sustained ischaemia could indeed be involved in precon-
ditioning-induced cardioprotection. 
Conclusions
Our work thus far on the mechanism of ischaemic precondition-
ing has identified beta-adrenergic stimulation as an important 
trigger in the process. Careful elucidation of downstream signal-
ling indicated activation of the stress kinase p38 MAPK as a trig-
ger, while attenuation of its activation during sustained ischaemia 
and reperfusion was associated with a reduction in necrosis and 
apoptosis. Experimental manipulation of p38 MAPK activation 
suggested a possible causal role in triggering cardioprotection. 
How the attenuated activation of this stress kinase during ischae-
mia and reperfusion is linked to cardioprotection remains to be 
established. 
Recently, attention has shifted to events during early reper-
fusion where activation of the so-called RISK pathway (ERK 
and PKB/Akt) and inhibition of the formation of the mitochon-
drial permeability transition pore have been suggested to be the 
final effector of cardioprotection.5,6,9 Since it is believed that the 
kinases are merely signalling molecules that carry the protective 
signal, it remains to be established whether and how p38MAPK 
is linked to these final effectors in cardioprotection.
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